Details of Disease

General Information of Disease (ID: DISHYPKS)

Disease Name Recurrent glioblastoma
Synonyms glioblastoma neural subtype; neural glioblastoma
Disease Class 2A00: Brain cancer
Definition A molecular subtype of glioblastoma characterized by the expression of the neural markers NEFL, GABRA1, SYT1, and SLC12A5.
Disease Hierarchy
DISI0V5E: Glioblastoma
DISHYPKS: Recurrent glioblastoma
ICD Code
ICD-11
ICD-11: 2A00.00
ICD-10
ICD-10: C71
Expand ICD-9
140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,202.8,208.9,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229
Disease Identifiers
MONDO ID
MONDO_0000460
UMLS CUI
C3828832
MedGen ID
821580

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Capmatinib DMYCXKL Approved Small molecular drug [1]
Nivolumab DMAB9QE Approved Monoclonal antibody [1]
Coenzyme Q10 DM8D9H5 Phase 4 Small molecular drug [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Approved
Drug Name Drug ID Highest Status Drug Type REF
Relatlimab DM28AZV Approved NA [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 65 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bavituximab DMCGW5R Phase 3 Monoclonal antibody [1]
DCVax-Ovarian DMBLASN Phase 3 NA [3]
Disufenton sodium DMJS8V3 Phase 3 Small molecular drug [1]
ICT-107 DMBIZ7H Phase 3 Vaccine [3]
INCB24360 DMIJGT9 Phase 3 Small molecular drug [2]
Napabucasin DMDZ6Q3 Phase 3 NA [2]
Selinexor DMBD4K3 Phase 3 Small molecular drug [1]
SYM-004 DMOVEDH Phase 3 Antibody [4]
TRC105 DM1874J Phase 3 Monoclonal antibody [1]
VAL-083 DM9J5Q4 Phase 3 Small molecular drug [2]
VB-111 DMX04CA Phase 3 NA [1]
Vitespen DMZ8BZ2 Phase 3 NA [2]
OT-101 DMCTRLN Phase 2/3 Antisense oligonucleotide [1]
ABT-414 DMGUTPN Phase 2 Antibody [4]
Ad-RTS-hIL-12 DMCNTFW Phase 2 Gene therapy [1]
ANG1005 DMV5ENT Phase 2 NA [1]
BGB-290 DMRO6XT Phase 2 NA [1]
Cotara DMSCHEZ Phase 2 NA [5]
Derlotuximan biotin DM8IBC6 Phase 2 NA [4]
Dicopp DM6IR9R Phase 2 NA [1]
Disufenton DMYC2LE Phase 2 Small molecular drug [6]
DNX-2401 DMDQ3XP Phase 2 Oncolytic virus therapy [7]
ERC-1671 DMKJ7WA Phase 2 NA [3]
GBM-Lamp-Vax DMCWHSA Phase 2 NA [3]
Ifabotuzumab DMGWNCJ Phase 2 NA [2]
INO-5401 DMXX3EW Phase 2 Vaccine [1]
KD019 DMEFW3G Phase 2 Small molecular drug [1]
NVX-108 DM3LWFJ Phase 2 NA [1]
Poly-ICLC DM2570B Phase 2 Small molecular drug [1]
Prophage cancer vaccine DM3L1C6 Phase 2 NA [3]
PT2385 DMCSN69 Phase 2 NA [1]
Selinexor oral DMDLOBZ Phase 2 NA [2]
SGT-53 DMLYIPA Phase 2 Gene therapy [8]
TPI 287 DM3I5NU Phase 2 NA [1]
TRC102 DMPGDKG Phase 2 NA [2]
TTAC-0001 DM6TAFE Phase 2 Antibody [9]
TV-Brain-1 DMVL95E Phase 2 NA [3]
TVI-Brain-1 cancer vaccine DM776EU Phase 2 NA [1]
Varlilumab DMQSC5O Phase 2 NA [4]
Verubulin DMBQC3L Phase 2 Small molecular drug [2]
Ad-IL-12 DNA therapeutic DMB19IO Phase 1/2 NA [2]
Anti-EGFRvIII CAR transduced PBL DMDKTYU Phase 1/2 CAR T Cell Therapy [10]
AU101 DMLAKPI Phase 1/2 NA [1]
AU105 DMPAZ3U Phase 1/2 NA [1]
BAL-101553 DMPFGL8 Phase 1/2 Small molecular drug [1]
PEPIDH1M DM9V66I Phase 1/2 NA [3]
TG02 DMZFIGQ Phase 1/2 Small molecular drug [1]
WP-1066 DMUGHWR Phase 1/2 Small molecular drug [1]
2X-111 DMMK4J7 Phase 1 NA [1]
AMG 596 DM4G1SP Phase 1 Antibody [1]
Anti-LAG3 mAb DMJ9OYX Phase 1 NA [2]
AZD1390 DMYBX4N Phase 1 NA [1]
BXQ-350 DMKJO3A Phase 1 Recombinant protein [1]
CART-EGFRvIII T cells DMGPR1C Phase 1 CAR T Cell Therapy [11]
CC-122 DM0SRAN Phase 1 Small molecular drug [2]
Cerebral EDV DMEHOZB Phase 1 NA [1]
DNA-2401 DMC9LTE Phase 1 NA [1]
EGFRvIII CAR T cells DM6XWV4 Phase 1 CAR T Cell Therapy [12]
EGFRvIII-CARs DMA46RN Phase 1 CAR T Cell Therapy [13]
HER2-specific T cells DM7UJ6E Phase 1 CAR T Cell Therapy [14]
HER2.taNK DMWKDT9 Phase 1 NA [2]
ICT-121 DM64LVS Phase 1 Vaccine [3]
MB-101 DMLA1QD Phase 1 NA [1]
PAC1 DMYQUIP Phase 1 Small molecular drug [1]
RQNestin 34.5 DM5BHCW Phase 1 Oncolytic virus [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 65 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT00677716) Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse. U.S. National Institutes of Health.
6 ClinicalTrials.gov (NCT04388475) Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma. U.S. National Institutes of Health.
7 ClinicalTrials.gov (NCT02798406) Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT02340156) Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma. U.S. National Institutes of Health.
9 ClinicalTrials.gov (NCT03856099) TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab. U.S. National Institutes of Health.
10 ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
11 ClinicalTrials.gov (NCT03726515) CART-EGFRvIII + Pembrolizumab in GBM
12 ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
13 ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
14 ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
15 ClinicalTrials.gov (NCT03152318) A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide. U.S.National Institutes of Health.